Author: Yatiri Bio

Posted Date:

March 24, 2026

Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML

Yatiri Bio

March 24, 2026
Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286

Yatiri Bio

February 10, 2026